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Characterization of a functional C3A liver spheroid
model†
Harriet Gaskell,a,b Parveen Sharma,*a Helen E. Colley,c Craig Murdoch,c
Dominic P. Williamsb and Steven D. Webbd
More predictive in vitro liver models are a critical requirement for preclinical screening of compounds
demonstrating hepatotoxic liability. 3D liver spheroids have been shown to have an enhanced functional
lifespan compared to 2D monocultures; however a detailed characterisation of spatiotemporal function
and structure of spheroids still needs further attention before widespread use in industry. We have develo-
ped and characterized the structure and function of a 3D liver spheroid model formed from C3A hepa-
toma cells. Spheroids were viable and maintained a compact in vivo-like structure with zonation features
for up to 32 days. MRP2 and Pgp transporters had polarised expression on the canalicular membrane of
cells in the spheroids and were able to functionally transport CMFDA substrate into these canalicular
structures. Spheroids expressed CYP2E1 and were able to synthesise and secrete albumin and urea to a
higher degree than monolayer C3A cultures. Penetration of doxorubicin throughout the spheroid core
was demonstrated. Spheroids showed increased susceptibility to hepatotoxins when compared to 2D cul-
tures, with acetaminophen having an IC50 of 7.2 mM in spheroids compared to 33.8 mM in monolayer
culture. To conclude, we developed an alternative method for creating C3A liver spheroids and demon-
strated cellular polarisation and zonation, as well as superior liver-speciﬁc functionality and more sensitive
toxicological response compared to standard 2D liver models, conﬁrming a more in vivo-like liver model.
Introduction
Drug-induced liver injury (DILI) is a common side-eﬀect of
many therapeutic compounds and often results in the failure
of drugs in discovery and development resulting in thera-
peutics not reaching the market, or being withdrawn.1
Exposure to hepatotoxic compounds can result in liver failure,
a life threatening condition, usually requiring a liver trans-
plant.2,3 Predictive in vitro liver models are essential during
initial drug screening in order to conduct an accurate risk
assessment leading to better candidate selection early in the
drug discovery and development process. A commonly used
in vitro model to detect liver injury are freshly isolated human
hepatocytes cultured as a monolayer, suspension or sandwich
culture.4 However the rapid decline in function and viability of
these cells ex vivo and inter-donor variability are a major limit-
ation to their use.5–8 Immortalised hepatocarcinoma cell lines,
such as HepG2, C3A, Huh7 and HepaRG, have been used as an
alternative to freshly isolated hepatocytes since they have
extended lifespans and their clonal nature reduces inter-experi-
mental variability.6,9 However when cultured as a 2D monolayer
these cell lines demonstrate low functionality and an altered
phenotype compared to human hepatocytes in vivo.4,9–11
A second disadvantage of commonly used in vitro models is
a lack of 3D structure, which has a significant eﬀect on the
hepatocyte morphology, function, phenotype, signalling and
toxicological response.12–14 A simple, high-throughput method
of culturing cells in 3D is by creating spheroids. Spheroids,
also known as microtissues or organoids, are spherical 3D
clusters of cells with direct cell–cell contacts that can be
formed using a variety of techniques with or without the use
of scaﬀolds.4,15–18 Additionally, spheroids have the potential to
be used for long-term repeat dose studies as well as being
amenable to high-throughput assays, an advantage for drug
screening.15,17 Unlike more complicated 3D cell culture tech-
niques, such as perfused cultures, bioreactors, scaﬀold or
chip-based systems, spheroids are simple to generate, in-
expensive to culture, reproducible and easy to analyse.4 The
use of spheroids as a model for screening of hepatotoxins is
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fairly novel; however in other areas of research spheroids are a
well-established 3D cell culture technique. So far research into
liver spheroids has shown some promising results. When cul-
tured in spheroids isolated human hepatocytes survive for up
to 4 weeks, sustaining important functions such as phase I
and II enzyme expression, albumin and urea synthesis and
expression of liver-specific markers.19,20 Furthermore bile
canaliculi structures can be visualised in the spheroids, indi-
cating that the hepatocytes are polarised and retain their
in vivo-like morphology and phenotype.11,20 Additionally, when
cultured in spheroids, hepatocytes show cuboidal morphology,
enhanced cell–cell contacts and production of extracellular
matrix components.15,21
Multiple studies have also shown that hepatocarcinoma cell
lines cultured in 3D have superior liver-specific functionality
when compared to monolayer cultures, overcoming one of the
main disadvantages of these cells. HepaRG cells have been cul-
tured as spheroids and show a significant improvement in
albumin and AboB production, increases in liver specific gene
expression and activity, and induction of CYP enzymes when
compared to 2D cultured cells.22–24 Spheroids created from
Huh7 cells also display superior function, with expression of
phase I and II enzymes as well as polarisation of multiple
receptors.25 Novel cell lines such as upcyte hepatocytes have
also been considered as an alternative to primary cells and
express hepatocyte specific markers and functional phase I
and II metabolism when cultured as spheroids.26 HepG2 cell
spheroids have successfully been cultured by multiple research
groups and have shown to be viable and functional for at least
28 days, determined by increased albumin production,
increased expression of liver specific enzymes and activity of
phase I and II enzymes, increased sensitivity to hepatotoxins,
bile canaliculi formation and transporter function.27–29 In
addition to this, spheroids formed from HepG2 cells show
over-expression of genes involved in xenobiotic and lipid
metabolism.20,22,23,25,28,30 This increase in liver-specific func-
tion has been shown to raise the sensitivity of HepG2 cells to
hepatotoxic compounds and the enhanced lifespan allows for
more realistic repeat dosing strategies.28 C3A cells are a sub-
clone of HepG2 cells with some advantages, selected for their
strong contact-inhibited growth characteristics, as well as
high-albumin production, alpha fetoprotein and transferrin
synthesis and the ability to grow in glucose deficient media.31
This cell line therefore has advantages over others when cul-
tured in spheroids, with a reduced proliferation rate, more
representative of the in vivo situation.32,33 Previous studies of
C3A spheroids have revealed superior function over 2D
cultures,32–34 however further investigation into the canalicular
structures, zonation, liver-specific functionality and toxicologi-
cal response of this model is necessary before widespread use
during drug screening.
3D liver spheroids show promise through enhanced func-
tionality compared to 2D cultures, and could provide a valu-
able tool for investigating hepatotoxic drugs in pre-clinical
safety testing. However, despite the increasing interest and use
of 3D liver models, limited research has gone into validating
key structural and functional parameters such as cellular mor-
phology and polarisation, secondary structures, oxygen and
nutrient diﬀusion, zonation, drug penetration, liver-specific
functionality and the ability to predict hepatotoxic
potential.35–37 In this study we developed and optimised a liver
spheroid model using C3A hepatocarcinoma cells and charac-
terised their spatiotemporal structure and function providing
essential optimising parameters and an invaluable tool for
investigating acute and chronic liver injury.
Experimental
Spheroid formation and growth
C3A cells were maintained in EMEM (LGC Standards) sup-
plemented with 10% FBS and 1% penicillin–streptomycin
under standard cell culture conditions. For 2D monolayer
experiments C3A cells were seeded and left to adhere for
24 hours and confirmed to be 100% confluent before analyses.
Spheroids were created using the liquid overlay technique
as previously described.38 Briefly, 100 µl of sterile 1.5%
Agarose (high gelling temperature-Sigma Aldrich) in EMEM
was added per well to flat-bottomed 96-well cell culture plates
to form a low-adherence surface. Additionally Ultra Low Adher-
ence plates (ULA-Corning) were used as a comparison. C3A
cells were seeded at 500, 750, 1000, 1500, 2000 or 2500 cells
per well in 100 µl media and left for 72 hours to form spher-
oids. Media was renewed twice weekly and spheroids were cul-
tured for up to 32 days. Images of spheroids in culture were
taken by phase-contrast microscopy through 4× objective and
maximum spheroid diameter measured.
Histological analysis
Spheroids were washed in PBS, fixed for 1 hour in 4% PFA and
embedded in 2% Agarose (low EEO-Sigma Aldrich) in 4% PFA
then paraﬃn embedded. Tissue sections were cut and stained
with haematoxylin and eosin (H&E) or as previously
described.39 Immunohistochemistry for Ki-67, carbamoyl-
phosphate synthase 1 (CPS1) and CYP2E1 was carried out by
the Department of Veterinary Pathology, Leahurst Campus,
University of Liverpool, UK.
Immunofluorescence analysis of spheroids
Spheroids were transferred to ULA plates, washed three times
in PBS and fixed with 4% PFA for 1 hour at 4 °C. Spheroids
were washed again then permeabilized with 0.5% Triton X-100
in Tris-Buﬀered Saline with 0.05% Tween20 (TBST) overnight
at 4 °C and then blocked with 0.1% Triton X-100/3% BSA in
TBST for 2 hours at room temperature (RT). Primary anti-
bodies Multidrug resistance protein-2 (MRP2-Abcam) and
P-glycoprotein (Pgp-Abcam) were diluted 1 : 20 in 0.1% Triton
X-100/1% BSA in TBST were incubated with the spheroids over-
night at 4 °C. Spheroids underwent three 1 hour washes with
1% Triton X-100 in TBST then incubated with secondary Alexa
Fluor 488 Donkey Anti-Mouse antibody (Life Technologies)
diluted 1 : 1000, Hoechst diluted 1 : 5000 and Phalloidin 568
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diluted 1 : 250 in 0.1% Triton X-100/1% BSA in TBST overnight
at 4 °C. Spheroids were finally washed for 1 hour then
mounted with Prolong Gold (Life Technologies) onto a glass
microscope slide. Maximum intensity projection images of
spheroids were taken using a Zeiss Axio Observer microscope
with Apoptome using 40× oil objective.
Immunofluorescence analysis of 2D monolayers
Cells were washed in PBS for 30 min at 4 °C then fixed with
2% PFA for 30 min at 4 °C. Cells were permeabilized with two
15 min washes in 0.2% Tween-20/0.5% Triton X-100 in PBS at
4 °C and blocked for 30 min in 5% BSA/0.2% Tween-20/0.5%
Triton X-100 in PBS at room temperature. Primary antibodies
MRP2 and Pgp were diluted in 5% BSA/0.2% Tween-20/0.5%
Triton X-100 in PBS and incubated with cells overnight at 4 °C.
Cells underwent three 15 min washes in 0.2% Tween-20/0.5%
Triton X-100 in PBS then incubated with secondary Alexa Fluor
488 Donkey Anti-Mouse antibody diluted 1 : 1000, Hoechst
diluted 1 : 5000 and Phalloidin diluted 1 : 250 in 5% BSA/0.2%
Tween-20/0.5% Triton X-100 in PBS for 1 hour at room temp-
erature. Cells underwent three 15 min washes in PBS then
were mounted with Prolong gold onto a glass microscope
slide. Images were taken using a Zeiss Axio Observer micro-
scope with Apoptome using 40× oil objective.
Analysis of transporter function
Spheroids and monolayers were incubated with 5 µM 5-chloro-
methylfluorescein diacetate (CMFDA-Life Technologies) with
or without 25 µM MK571 (MRP inhibitor) and 12.5 µM PSC833
(Pgp inhibitor) in EMEM for 30 min at 37 °C. CMFDA is mem-
brane permeable until it enters cell and is converted to gluta-
thione-methylfluorescein (GSMF), a cell impermeable
substrate for MRP and Pgp.40 Cells and spheroids were washed
in PBS and prepared for immunofluorescence as described
above.
Quantification of albumin and urea production
Albumin and urea in spheroid and monolayer supernatant
were quantified using Albumin Human ELISA Kit (Abcam) and
Urea Assay kit (Abcam) respectively, according to the manufac-
turer’s protocol. Samples were collected 4 days after media
change, twice weekly over 32 days. Data was normalised to
account for diﬀerences in cell number.
Quantification of Keratin 18
Total Keratin 18 and cleaved Keratin 18 in spheroid super-
natant were quantified using M65 and M30 ELISA kits (Peviva)
respectively, according to the manufacturer’s protocol. Apopto-
tic cell death was represented by the Cleaved Keratin 18 con-
centration, total cell death represented by total Keratin 18, and
necrotic cell death calculated from the total cell death minus
apoptotic cell death.
Visualisation of compound penetration
Spheroids were treated with 3 µg per ml doxorubicin for
24 hours then washed in PBS, fixed in 4% PFA for 1 hour then
incubated with Hoechst diluted 1 : 5000 in 0.1% Triton X-100
/1% BSA in TBST for 1 hour. Images were taken using a Zeiss
LightSheet Z.1 microscope.
Toxicological analysis
Spheroids were treated at day 3 of culture with hepatotoxic
compounds acetaminophen, fialuridine, diclofenac and trova-
floxacin diluted in 0.5% DMSO in EMEM for 4 days with
repeat dosing on day 2. Monolayer C3A cells were treated with
compounds for 24 hours. Cell viability was analysed using Cell
Titer-Glo assay (Promega) according to the manufacturer’s
instructions and plotted as a percentage of untreated control.
Statistical analysis
Data expressed are representative of at least three independent
experiments (n = 3) in triplicate and represented as mean ±
standard error. Graphs and statistical analysis were performed
using GraphPad Prism 5 (Graphpad software, San Diego, CA,
USA).
Results
Optimisation of spheroid starting cell number
We initially compared two diﬀerent scaﬀold-free approaches to
create our C3A spheroids, the liquid-overlay technique and
ULA plates. Despite having similar growth characteristics,
spheroids created on ULA plates had an irregular, non-spheri-
cal structure with a less defined outer perimeter compared to
those formed using the liquid overlay technique, which were
consistently uniform and spherical (ESI Fig. 1†). We therefore
chose to perform all future experiments using the liquid-
overlay technique. We then assessed how diﬀerent starting cell
numbers may aﬀect spheroid formation, size and shape over
time. Spheroids were formed from a starting cell number of
500, 750, 1000, 1500, 2000 and 2500 C3A cells and cultured for
32 days. Brightfield microscopy was used to measure spheroid
diameter and morphology twice weekly (Fig. 1).
All starting cell numbers resulted in the formation of spher-
oids of varying sizes, with all of the cells in each well aggregat-
ing to form a single spheroid. Spheroids created from 500 cells
gradually increased in diameter over 32 days from 237.0 ±
14.3 nm to 432.9 ± 111.4 nm in diameter, however these spher-
oids were less uniform and less stable in shape, resulting in
disaggregation of some cells (Fig. 1A and B). However, spher-
oids with a starting cell number of 750 or 1000 cells steadily
grew over 32 days, 289.4 ± 26.5 nm and 343.2 ± 73.3 nm at day
4 and increasing to 407.7 ± 92.3 nm and 539.5 ± 39.5 nm at
day 32 respectively, and maintained a uniform spherical shape
over the course of the culture. Spheroids created with higher
starting cell numbers, 1500, 2000 or 2500 cells, increased in
diameter more rapidly, reaching much larger diameters of
624.5 ± 59.5 nm, 730.0 ± 112.0 nm and 759.1 ± 83.5 nm, as
well as becoming irregular in shape (Fig. 1A and B). From this
data, 750 cells was determined to be an optimal cell number
for creating spheroids, as these spheroids stayed the most
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uniform in shape over 32 days, with little variation in size and
the smallest diameter. 2500 cell spheroids have been sub-
sequently used in our analysis as a comparison.
Internal spheroid structure
In order to analyse the internal structure, H&E staining was
performed on spheroids with 750 and 2500 cell starting
numbers to visualise internal cell morphology and arrange-
ment over 32 days (Fig. 2). Staining of sectioned spheroids
with a starting cell number 750 cells revealed a compact,
uniform structure throughout the spheroid, with a defined
outer perimeter (Fig. 2). Cells within the spheroids had a
cuboidal 3D morphology with direct cell–cell contacts, similar
to that seen in a human liver. Correlating with cell growth
data, the 750 cell spheroids were seen to gradually increase in
size, yet stayed uniformly spherical with limited degrees of
necrosis up to day 32. However in the larger 2500 cell spher-
oids small patches of cell death started to occur around day 14
and, by day 18, a necrotic core had formed. This was con-
firmed by analysis of cell death biomarker release, revealing
significantly higher levels of necrosis in larger spheroids (ESI
Fig. 2†). Additionally, by day 25 the 2500 cell spheroids
became misshapen and their growth started to rapidly
increase, resulting in the spheroids disaggregating and losing
structural integrity (Fig. 2).
Proliferation of the cells inside the spheroid was analysed
over the first 18 days of culture using Ki-67 staining in spher-
oids with 750 and 2500 starting cell numbers (Fig. 3A). Nuclei
stain blue with haematoxylin and proliferating cells appear
brown, stained with Ki-67. At day 4, 59.5 ± 3.5% and 50.6 ±
2.3% of the cells in the spheroids were proliferating for 750 and
2500 starting cell numbers respectively (Fig. 3A and B). After 18
days in culture, fewer cells were seen to be proliferating, 32.4 ±
6.1% and 7.4 ± 1.3% respectively, with proliferating cells mainly
located nearer to the periphery of the spheroid (Fig. 3A).
The liver lobule can be classed as three regions, periportal,
transitional and perivenous regions which display zonation
due to the gradient of oxygen and nutrients available from the
Fig. 1 Eﬀect of starting cell number on spheroid size and morphology. Spheroids were created from 500, 750, 1000, 1500, 2000 and 2500 C3A
cells and cultured for 32 days. (A) Phase-contrast images of spheroids, images taken at day 7, 11, 14, 18, 21, 25, 28, 32. Scale bar = 100 µm.
(B) Growth curve of spheroids over 32 days. Spheroid diameter (µm) was plotted against culture time (days). Data are represented as mean ± standard
error (n = 3 in triplicate).
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Fig. 2 Spheroid internal structure and morphology. Spheroids were created on liquid-overlay plates from 750 or 2500 C3A cells and ﬁxed at day 4,
11, 18, 25 and 32 of culture, paraﬃn embedded, sectioned, stained with H&E. Images represent mid-sections through the spheroids. Scale bar =
100 µm.
Fig. 3 Proliferation of cells within the spheroids. Spheroids were created on liquid-overlay plates from 750 or 2500 C3A cells and ﬁxed at day 4, 11
and 18 of culture, paraﬃn embedded, sectioned and stained with ki67 (brown) to stain proliferating cells, and haematoxylin (blue) to stain the nuclei.
(A) Images of spheroid mid-sections. Scale bar = 100 µm; (B) Graph showing proliferating cells (%) plotted against culture time (days). Data are rep-
resented as mean ± standard error (n = 3).
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sinusoidal microvessels.41 CPS1 can be utilised as a zonation
marker for periportal areas of the liver.42 We stained spheroids
cultured for 18 days for CPS1 and found that it was expressed
near the periphery of the spheroid, an area with the highest
oxygen concentrations, similar to the periportal area of the
liver lobule (Fig. 4).
Cellular polarisation in spheroids
One of the key features of hepatocytes is their ability to polar-
ise. This involves the formation of bile canaliculi between adja-
cent cells, as well as the correct localisation of key transporters
to either the apical or canalicular membranes.4,43 We used
immunofluorescence to analyse the internal structure of the
spheroids over time. Spheroids were fixed and stained with
phalloidin (red) to visualise F-actin structures, by confocal
microscopy (Fig. 5). After 4 days of culture, F-actin filaments
were observed forming between cells within the spheroid
(Fig. 5A). After 11 days in culture, these larger structures could
be seen joining together to create a network throughout the
spheroid (Fig. 5B).
MRP2 and Pgp are transporters localised to the canalicular
membrane of hepatocytes and transport organic anions and
eﬄux lipophilic cations from the cell respectively.44 The
expression of these transporters were used to confirm whether
the actin structures observed were the result of cellular polaris-
ation and the formation of bile canaliculi. Spheroids and 2D
cultured C3A cells were analysed over 18 days for MRP2
(Fig. 6A) and Pgp (Fig. 6B) expression. The staining pattern of
these transporters emulated that seen with the phalloidin
(Fig. 5). The secondary structures could be seen forming from
day 4 of culture until at least day 18, regardless of spheroid
size (ESI Fig. 3†), and appeared to elongate and interconnect
over time, forming an interconnected network of canalicular
structures (Fig. 6). The same staining pattern for MRP2 and
Pgp was not seen in a 2D monolayer culture (Fig. 6).
Confirmation of liver-like function in spheroids
Transporter functionality was determined using fluorescently
labelled CMFDA. This compound can passively enter cells but
can only be eﬄuxed from cells via active transport through
MRP2 or Pgp.40 2D monolayer C3A cells retained CMFDA
(green) within the cell cytoplasm (Fig. 7). However in the
spheroids there was limited retention of CMFDA within cell
cytoplasm and an accumulation and co-localisation of the
compound within secondary canalicular-like structures, shown
by F-actin in red (Fig. 7). Blocking MRP and Pgp transporters
resulted in CMFDA being retained in the cell cytoplasm (ESI
Fig. 4†). This suggests that in the spheroids CMFDA was
actively transported out of the cells by MRP2 and Pgp into the
secondary structures, providing evidence that these transpor-
ters are functioning correctly.
In order to determine the presence of key liver-specific
enzymes we stained for CYP2E1, an important phase I meta-
bolic enzyme in the human liver. CYP2E1 was clearly expressed
throughout the spheroid, indicating that the spheroids
possess this liver-specific functional marker (Fig. 8).
Fig. 4 Zonation in spheroids. Spheroids were created on liquid-overlay
plates from 750 cells and ﬁxed at day 18 of culture, paraﬃn embedded,
sectioned and stained with CPS1, a periportal marker (brown), and
haematoxylin (blue) to stain the nuclei. Scale bar = 100 µm.
Fig. 5 Secondary structure formation in spheroids. Spheroids were cultured on liquid-overlay plates for (A) 4 days or; (B) 18 days, ﬁxed and stained
with Hoechst (blue) to stain the nuclei and phalloidin (red) to stain F-actin. Maximum intensity projection images were taken using a Zeiss Axio
Observer microscope. Scale bars = 100 µm and 50 µm respectively.
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Albumin and urea production from spheroids was quanti-
fied over 32 days. Albumin production gradually increased
from 36.9 ± 15.5 ng ml−1 at day 4 of culture to 878.9 ± 349.6 ng
ml−1 at day 32 (Fig. 9A). We compared this to 2D monolayer
cultured C3A cells which were seen to produce a maximum
82.3 ± 5.4 ng ml−1 albumin, significantly less than the values
obtained in 3D cultures. Similarly, urea production steadily
increased over 32 days from 6.2 ± 1.9 nmol ml−1 to 21.7 ±
2.0 nmol ml−1 (Fig. 9B). Monolayer cultured C3A cells pro-
duced significantly less urea, with a maximum of 2.6 ±
0.2 nmol ml−1.
Drug penetration throughout the spheroid
The assessment of acute and chronic drug toxicity is one of
the key applications of 3D spheroids. We next wanted to
confirm compound penetration and ascertain whether or not
Fig. 6 Transporter polarisation in spheroids. Spheroids were created from 750 C3A cells by liquid-overlay technique and compared to C3A cells cul-
tured in a 2D monolayer. Samples were ﬁxed at day 4, 11 and 18 of culture. Immunoﬂuorescent staining was performed for the canalicular transpor-
ter (A) MRP2 (green) or; (B) Pgp (green) and Hoechst (blue) to stain the nuclei. Maximum intensity projection images were taken using a Zeiss Axio
Observer microscope. Scale bars = 50 µm.
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all the cells within the spheroids are being exposed to com-
pounds added exogenously. In order to analyse compound
penetration 11 day old 750 cell spheroids (estimated to be
around 263 μm in diameter, Fig. 1B) were treated with doxo-
rubicin, an autofluorescent chemotherapeutic compound with
a molecular mass of 543 g mol−1 and a log P of 1.27, and
imaged using LightSheet microscopy. Separate images were
taken throughout the z-plane of the spheroid to visualise the
entire spheroid core. Fig. 10 shows the spheroid after treat-
ment with doxorubicin (green) for 24 hours, with nuclei
shown in blue. Doxorubicin can be seen fluorescing through-
out the spheroid core in the median section through the
spheroid (Fig. 10A), as well as throughout the periphery
(Fig. 10B), thus confirming that this compound is in contact
with every cell in the spheroid. From this we can assume that
the majority of cells in the spheroid will be exposed to similar
concentrations of an exogenously treated compound.
Toxicological analysis
Spheroids were treated with varying concentrations of hepato-
toxic compounds and compared to C3A cells cultured as a 2D
monolayer. A repeat-dosing regimen could be used for spher-
oids, as we have previously confirmed their viability and func-
tionality over this period; however 2D monolayer cultures were
given acute doses as these cells become over-confluent and
loose viability once cultured for over 48 hours. Dose-dependent
reduction in cell viability was observed in the spheroids in
response to all 4 hepatotoxins (Fig. 11). Table 1 lists the IC50
values calculated for each compound in C3A spheroids com-
pared to monolayer cultures. For example acetaminophen was
significantly more toxic to spheroids than monolayer cultures,
with an IC50 value of 7.2 mM in spheroids and 33.8 mM in
monolayers. Spheroids were also significantly more sensitive
to trovafloxacin, with an IC50 value of 65 µM in spheroids com-
Fig. 7 Transporter function in spheroids. Spheroids were created from 750 C3A cells on liquid-overlay plates or C3A cells were cultured in a
20 monolayer on glass coverslips for 4, 11 or 18 days and then incubated with CMFDA (green) an MRP and Pgp transporter substrate for 30 min,
washed, ﬁxed and stained with Hoechst (blue) to stain the nuclei and phalloidin (red) to stain F-actin. Images were taken using a Zeiss Axio Observer
microscope. Dotted line indicates an example of a cell where CMDFA is retained within the cell cytoplasm. Arrow indicates the canalicular-like struc-
tures containing CMFDA. Scale bars = 50 μm.
Fig. 8 CYP2E1 enzyme expression in spheroids. Spheroids were created
on liquid-overlay plates from 750 cells and ﬁxed at day 11 of culture,
paraﬃn embedded, sectioned and stained with CYP2E1 (brown) and
haematoxylin (blue) to stain the nuclei. Scale bar = 100 µm.
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pared to 440 µM in 2D cultures, as well as fialuridine, which
had an IC50 value of 206 µM in 3D culture and 380 µM in 2D
(Table 1). In the monolayer cultures diclofenac did not have a
toxic response at the concentrations used, although the IC50
value is reported to be around 763 µM in HepG2 monolayer
cultures45 and was found to be 295 µM in spheroid cultures
and significantly more toxic (Fig. 11).
Discussion
3D in vitro models are becoming more widely used when inves-
tigating drug toxicity. Numerous companies now oﬀer spher-
oids to be shipped ready for use in drug toxicity testing.
Research has shown the potential for liver spheroid models to
predict hepatotoxicity more precisely than commonly used 2D
Fig. 9 Albumin and urea production in spheroids. Spheroids were created from 1000 C3A cells on liquid-overlay plates and C3A monolayer cultures
used as a comparison. (A) Albumin and, (B) urea release were quantiﬁed in spheroid (black circle) and monolayer (black square) supernatant and
plotted again culture time (days). Data are represented as mean ± standard error (n = 3 in triplicate).
Fig. 10 Drug penetration throughout the spheroid. Spheroids were cultured on liquid-overlay plates for 11 days, treated with 3 µg per ml doxo-
rubicin (green) for 24 hours, ﬁxed, stained with Hoechst (blue) to stain the nuclei and imaged by Zeiss LightSheet Z.1 microscope. (A) Represents a
mid-section through the spheroid and; (B) a maximum projection image. Scale bars = 50 µm.
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liver models, as well as spheroids being more amenable to
high-throughput screening and long-term repeat dose studies.
However many structural and functional characteristics of liver
spheroids have not been fully investigated, as well as minimal
comparison between the functionality and toxicological predic-
tivity of liver spheroids and other 2D models.
We have developed a technique for creating liver spheroids
from the C3A cell line. C3A cells, a derivative of HepG2 cells,
were chosen for this model as they exhibit strong contact-
inhibited growth characteristics, therefore when cultured in a
spheroid these cells do not proliferate to the same extent as
other hepatocarcinoma cell lines.33 This emulates primary
cells which bear limited proliferation capacity. Other advan-
tages include unlimited lifespan, stable phenotype and
absence of donor variation.6,9 As with other liver cell lines,
C3A cells have clear disadvantages when cultured in 2D,
including limited expression of metabolizing enzymes and
lack of liver-specific functions,9,10 however research is now
emerging that indicates 3D culture may overcome some of
these key issues. Previous work has been published on C3A
spheroids, such as Wrzesinski’s group, who used AggreWell
plates to create their aggregates and cultured them in micro-
gravity bioreactor.32–34 Extensive characterisation of spheroid
growth and viability was performed, as well as determining
increases in urea and cholesterol synthesis over 42 days of
culture, changes in gene expression and a toxicological
response comparable to in vivo.32–34 We adopted an alternative
scaﬀold free approach for creating spheroids in order create
direct cell–cell contacts and to reduce any deleterious eﬀects
of extracellular matrix components or scaﬀolds.12–14
In this study, we created and characterised uniform, repro-
ducible C3A spheroids using the liquid-overlay technique,
which has not been previously reported to have been used
with this cell line. We found that this technique was superior
to the ULA plate’s method, a similar scaﬀold-free technique,
creating more uniform, spherical aggregates. The liquid-
overlay technique was reliable and reproducible, forming struc-
turally stable spheroids in every experiment in every well. This
method was a highly user-friendly system as it does not
require an extensive tissue engineering background, and the
cost-eﬀectiveness of the model and amenability to both high-
throughput and repeat-dose studies makes it a promising
model for toxicological studies. Spheroids created from 750
Fig. 11 Spheroids show sensitivity to hepatotoxins. Spheroids were created from 1000 C3A cells by liquid-overlay technique and cultured for
3 days, using 2D monolayer C3A cells as a comparison, and treated with (A) acetaminophen; (B) diclofenac; (C) trovaﬂoxacin and (D) ﬁaluridine. Cell
viability was analysed and plotted as a percentage of untreated control. Data are represented as mean ± standard error. ****p < 0.0001, ***p < 0.001,
**p < 0.01, *<0.05 (n = 3 in triplicate).
Table 1 Toxicological analysis of spheroids. Spheroids were created
from 1000 C3A cells by liquid-overlay technique, using 2D monolayer
C3A cells as a comparison, and treated with 4 hepatotoxins. Cell viability
was analysed IC50 values calculated. Data are represented as mean
values (n = 3 in triplicate)
Compound
IC50 value in C3A
spheroids (μM)
IC50 value in C3A 2D
monolayer (μM)
Paracetamol 7212 33 826
Diclofenac 295 Non toxic
Trovafloxacin 65 440
Fialuridine 206 380
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cells were viable for at least 32 days and remained relatively
small, with a maximum diameter of 407.8 ± 92.3 nm, and uni-
formity in shape and size. Proliferation of cells within the
spheroids decreased over time, similar to that seen with
HepG2 spheroids.28 Histological analysis revealed a cuboidal
cell morphology within the spheroids, with direct cell–cell con-
tacts similar to an in vivo liver structure, unlike in 2D liver cell
models where the cells have altered cell morphology, including
an elongated and flattened structure, with cell contacts only in
one plane, therefore limiting cell signalling.12,14 Additionally
our spheroids recapitulate the zonation of the liver that occurs
in vivo due to oxygen and nutrient gradients. We confirmed
this by staining for the periportal marker CPS1, which is
expressed in areas nearest to the oxygenated blood supply in
the liver and can be seen staining the peripheral regions on
the spheroid in a similar expression pattern, indicating spatio-
temporal similarity compared to the human liver.42
One disadvantage of using spheroids for drug testing is
that cell death can occur within the spheroid core, distorting
toxicity data. It has been suggested that oxygen and nutrients
can diﬀuse through tissue approximately 100 µm,35–37 however
little research has gone in to specifically determining the size
or time at which liver spheroids develop necrosis in the core,
which may well depend of the cell type, cell number, scaﬀold
interactions and culture conditions. We have found in our
model that 750 C3A cells is an optimum starting cell number
and a culture period of 32 days in which liver spheroids do not
possess a visible necrotic core, with minimal apoptosis and
necrosis, reaching a size of approximately 400 µm. However we
also revealed that once the C3A spheroids developed using our
method exceed 700 µm in diameter a necrotic core develops
and increasing levels of necrotic biomarkers are observed.
Henceforth, C3A spheroids exceeding this critical size cannot
be used to accurately determine the eﬀect of a toxicological
compound since they are likely to have a pre-existing necrotic
core which would give unrepresentative results. The size of the
spheroid is therefore an essential parameter that should be
taken into account in toxicological studies.
In vivo, hepatocytes are structurally and functionally
polarised,4,43 and we have recapitulated this phenotype in our
spheroids. Secondary structures composed of actin can be
observed forming enhanced networks throughout the spher-
oids, which has been previously reported in other studies.28,46
We confirmed that these structures were a result of cellular
polarisation by staining for MRP2 and Pgp, transporters
known to be expressed and localised to the canalicular mem-
brane of hepatocytes in vivo.43 MRP2 transporter function has
been proven in HepG2 spheroids,29 but has not previously
been investigated in a C3A spheroid model. MRP2 and Pgp
transporter function was confirmed in our C3A spheroids in
an experiment utilising CMFDA, a substrate actively trans-
ported out of cells by functional canalicular transporters.40 We
witnessed accumulation of CMFDA in the bile canalicular
structures of our spheroids, with little remaining within the
cell, revealing that MRP2 and Pgp transporters in the spheroid
are functional. This was not observed for monolayer cultured
C3A cells, suggesting lack of expression of MRP2 and Pgp,
improper polarisation or localisation, or inactive transporters
when cultured in 2D. As another indicator of liver-specific
function, we stained for CYP2E1,42 an important phase I meta-
bolic enzyme. We confirmed expression of CYP2E1 throughout
the spheroid at day 18 of culture, similar to HepG2 spheroids
where maximal expression was seen on day 21 to 28 of
culture.28 We additionally found that our spheroids were able
to synthesise and secrete albumin and urea, with a gradual
increase in production over 32 days of culture and around ten
times more than that produced in 2D monolayer C3A cells.
Albumin and urea production are important physiological
functions of hepatocytes in vivo, therefore this data provided
further evidence of liver-specific functionality in our spher-
oids, as and builds on the finding that cells cultured in 3D
have superior functionality to those cultured in 2D.47
One complication when comparing 2D monocultures to
spheroids is whether or not the cells in both models are
exposed to the same concentrations of drug compounds. By
using LightSheet microscopy we have confirmed that the
chemotherapeutic drug doxorubicin can penetrate into cells in
the core of a spheroid with a diameter of around 263 μm. This
allows us to assume that all cells within the treated spheroids
were exposed to similar concentrations of doxorubicin,
although the exact concentration cannot be quantified using
this technique. We can however predict that other compounds
with similar physicochemical properties to doxorubicin (mole-
cular mass 543 g mol−1, log P of 1.27) would also be able to
penetrate the C3A spheroids, enabling us to utilise this model
for drug toxicology studies.
We analysed the toxicological predictivity of our C3A spher-
oids by treating them with a variety of hepatotoxins, each of
which cause toxicity by a diﬀerent mechanism,48–50 and com-
pared this to standard 2D monolayer cultures of the same cell
type. We were able to utilise a repeat-dosing strategy in our
spheroids as we had previously confirmed that they were
viable and functional over this time course. IC50 values were
calculated, as this is an industry standard for determining
whether or not an in vitro model can detect a toxic response.
Spheroids were found to be more susceptible to toxicity from
these hepatotoxic compounds than 2D cultures, indicated by
lower IC50 values in the spheroid model. This proves that the
3D spheroid model is more sensitive to hepatotoxins than
standard 2D models and superior at predicting whether or not
a compound is likely to cause hepatotoxicity in humans.
Conclusion
Spheroids have promise to be adopted as an in vitro liver
model for safety screening, displaying an enhanced functional
lifespan for repeat-dose studies and amenability to high-
throughput screening. We have successfully developed a repro-
ducible technique for creating uniform C3A spheroids and
characterised their growth and proliferation characteristics
over 32 days. Our spheroids display an in vivo-like structure,
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direct 3D cell–cell contacts, zonation and structural and func-
tional polarisation. We additionally confirmed liver-specific
functions such as the ability to synthesise and secrete albumin
and urea, functional canalicular transporters and CYP2E1
expression. Toxicological analysis of 4 known hepatotoxins indi-
cated that our spheroid model can predict hepatotoxic potential
with a higher sensitivity than standard 2D monolayer cultures.
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